Loading…
Rigel Pharmaceuticals, Inc. is projected to rise to $34.71 by 2027, a +18% move from its current price of $29.48. RIGL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.54 | $29.48 | $30.44 | -0.01% |
| May 30 | $28.16 | $29.47 | $30.85 | -0.03% |
| May 31 | $27.87 | $29.47 | $31.16 | -0.04% |
| Jun 1 | $27.63 | $29.46 | $31.42 | -0.05% |
| Jun 2 | $27.41 | $29.46 | $31.66 | -0.06% |
| Jun 3 | $27.22 | $29.46 | $31.87 | -0.08% |
| Jun 4 | $27.05 | $29.45 | $32.07 | -0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $27.05 | $29.45 | $32.07 | -0.09% |
| Week 2 | $26.09 | $29.43 | $33.19 | -0.18% |
| Week 3 | $25.37 | $29.40 | $34.08 | -0.27% |
| Week 4 | $24.77 | $29.37 | $34.83 | -0.36% |
| Week 5 | $24.26 | $29.35 | $35.51 | -0.45% |
| Week 6 | $23.80 | $29.32 | $36.13 | -0.54% |
| Week 7 | $23.38 | $29.30 | $36.70 | -0.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rigel Pharmaceuticals, Inc. is a biotechnology company that develops and provides therapies to improve the lives of patients with hematologic disorders and cancer in the United States. Its portfolio includes TAVALISSE for adult patients with chronic immune thrombocytopenia; REZLIDHIA for relapsed or refractory (R/R) AML with a susceptible IDH1 mutation as detected by an FDA-approved test; and GAVRETO for RET fusion-positive NSCLC and RET fusion-positive thyroid cancer.
The company also develops R289, an oral IRAK1/4 inhibitor, which is being advanced to Phase 1b for hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. Rigel has strategic development collaborations with The University of Texas MD Anderson Cancer Center (MDACC) for olutasidenib in IDH1-mutant cancers and with CONNECT to conduct a Phase 2 trial evaluating olutasidenib in combination with temozolomide for high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc.
was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals, Inc. (RIGL) is a biotechnology company with a portfolio addressing hematologic disorders and cancer. The stock is currently trading at $29.01 per share. Its market capitalization is $536.75M, and it holds a rank of 2986 by market capitalization.
The stock carries a long-run price outlook that projects a rising average price and substantial upside over time, with an average price of $29.01 in 2026 and a forecasted average of $195.57 by 2050, reaching a maximum of $395.87 in that year. The implied long-term ROI grows to 574.1% by 2050."
A major floor 22.4% below — a decisive break under it would weaken the trend.
The nearest floor, 11.7% below — buyers have tended to step in here.
The nearest ceiling, 10.2% above — a clean break opens room to run.
A major ceiling 28.7% above — clearing it would confirm fresh momentum.
Key RIGL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RIGL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.13 | Buy | $29.21 | Buy |
| MA 10 | $29.56 | Sell | $29.12 | Buy |
| MA 20 | $28.77 | Buy | $29.13 | Buy |
| MA 50 | $28.77 | Buy | $29.75 | Sell |
| MA 100 | $32.01 | Sell | $31.20 | Sell |
| MA 200 | $34.69 | Sell | $31.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.51 | Neutral |
| Stoch RSI (14) | 64.78 | Neutral |
| CCI (20) | 42.50 | Neutral |
| Williams %R (14) | -43.51 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 13.21 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 56.49 | Neutral |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -0.57 | Sell |
| Ultimate (7,14,28) | 58.51 | Neutral |
| Momentum (10) | 0.11 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 29.18 | Buy |
| ADX (14) | 12.67 | Neutral |
| ATR (14) | 0.74 | Info |
The 30-day range is $23.16 to $36.34. The RSI(14) is 50 and the 50-day simple moving average is $28.65 while the 200-day simple moving average is $34.70. The stock shows a support level at $26.04 and a resistance level at $32.49, with the overall sentiment described as NEUTRAL.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.44 | $29.48 | $37.14 | 0% | Neutral | |
| $27.05 | $34.71 | $47.46 | +18% | Neutral | |
| $33.10 | $43.88 | $62.51 | +49% | Bullish | |
| $34.76 | $47.37 | $69.69 | +61% | Bullish | |
| $37.98 | $53.03 | $80.18 | +80% | Bullish | |
| $38.59 | $55.12 | $85.33 | +87% | Bullish | |
| $37.34 | $54.46 | $86.13 | +85% | Bullish | |
| $39.46 | $58.71 | $94.65 | +99% | Bullish | |
| $47.09 | $71.41 | $117.19 | +142% | Bullish | |
| $56.18 | $86.75 | $144.73 | +194% | Bullish | |
| $64.78 | $108.75 | $194.32 | +269% | Bullish | |
| $107.18 | $208.54 | $411.63 | +607% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $25.44 | $29.48 | $34.50 | +0.00% |
| June 2026 | $24.30 | $28.65 | $34.66 | -2.82% |
| July 2026 | $24.47 | $29.14 | $35.81 | +1.71% |
| August 2026 | $23.83 | $28.60 | $35.58 | -1.84% |
| September 2026 | $22.62 | $27.32 | $34.32 | -4.48% |
| October 2026 | $22.84 | $27.75 | $35.18 | +1.59% |
| November 2026 | $23.73 | $28.98 | $37.02 | +4.44% |
| December 2026 | $23.51 | $28.86 | $37.14 | -0.42% |
Click any year to see its month-by-month RIGL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Rigel Pharmaceuticals, Inc.'s 2026 outlook centres on $29.48, within a $25.44 to $37.14 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, RIGL could reach as high as $47.46, with a base case around $34.71 and support toward $27.05 — roughly +18% from $29.48. Price action looks broadly range-bound.
Expect RIGL to range from $33.10 to $62.51 through 2028. The $43.88 average target implies a +49% move from current prices. That is up +26% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The RIGL price prediction for 2029 points to an average of $47.37 (low $34.76, high $69.69) — a potential gain of +61% on today's $29.48. Momentum favours further upside here.
In 2030, RIGL is projected to trade between $37.98 and $80.18, averaging $53.03 — a potential gain of +80% from today's $29.48. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Rigel Pharmaceuticals, Inc.'s 2031 outlook centres on $55.12, within a $38.59 to $85.33 range. That is up +4% on the projected 2030 average. That marks a +87% change versus current levels. Momentum favours further upside here.
By 2032, RIGL could reach as high as $86.13, with a base case around $54.46 and support toward $37.34 — roughly +85% from $29.48. Buyers look set to stay in control over this stretch.
Expect RIGL to range from $39.46 to $94.65 through 2033. The $58.71 average target implies a +99% move from current prices. That is up +8% on the projected 2032 average. Momentum favours further upside here.
The RIGL price prediction for 2034 points to an average of $71.41 (low $47.09, high $117.19) — a potential gain of +142% on today's $29.48. Buyers look set to stay in control over this stretch.
In 2035, RIGL is projected to trade between $56.18 and $144.73, averaging $86.75 — a potential gain of +194% from today's $29.48. That is up +21% on the projected 2034 average. Momentum favours further upside here.
Rigel Pharmaceuticals, Inc.'s 2040 outlook centres on $108.75, within a $64.78 to $194.32 range. That is up +25% on the projected 2035 average. That marks a +269% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, RIGL could reach as high as $411.63, with a base case around $208.54 and support toward $107.18 — roughly +607% from $29.48. Momentum favours further upside here.
Investing $1,000 in RIGL today (≈ 33.921303 RIGL) could be worth
$7,074.06
+$6,074.06 (+607%) by 2050 · US Dollar
Based on the average projected RIGL price of $208.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RIGLwould be worth at today's price.
$1,000 invested in RIGL on May 27, 2025 (≈ 50.968397 RIGL) would be worth
$1,502.55
+$502.55 (+50.3%) today · 1.50× · US Dollar
Based on a RIGL entry price of $19.62 vs. today's $29.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $28.82 | $1,022.9 | +2.3% |
| 1 month ago | $30.51 | $966.24 | -3.4% |
| 3 months ago | $35.71 | $825.54 | -17.4% |
| 6 months ago | $50.49 | $583.88 | -41.6% |
| 1 year ago | $19.62 | $1,502.55 | +50.3% |
| All time (5.0y) ago | $36.6 | $805.46 | -19.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RIGL forecast.
Our base-case forecast reaches $59.00 around 2034.
Implied market cap at $59.00: $1.09B
The multi-year forecast depicts a bullish trajectory beyond 2026, with the 2027 average price at $33.92 and the 2028 average at $42.96, rising further to a 2030 average of $51.85 and a 2030 max of $79.53, yielding an ROI of 78.7%. The outlook continues to strengthen through the decade, with the 2034 average at $68.56 and the 2035 average at $82.86, and a 2034 max of $114.58. By 2040, the average price is projected to $102.50 with a max of $187.15 and an ROI of 253.3%.
The 2050 forecast shows an average of $195.57, a max of $395.87, and an ROI of 574.1%, signaling substantial upside if the trajectory holds. These figures illustrate a rising long-term value path, but as with all forecasts, they are estimates and not guarantees, and actual results may differ based on market conditions and company developments.
Tap a question to reveal the answer.
2030: min $36.62, avg $51.85, max $79.53, ROI 78.7%, sentiment BULLISH.
The forecast shows a bullish trajectory beyond 2026, with the average price rising from $29.01 in 2026 to $195.57 by 2050 and ROI reaching 574.1% by 2050.
Yes. The 2040 forecast lists an average of $102.50 and a max of $187.15, indicating a path above $100. The 2034 max is $114.58, and the 2050 max is $395.87.
Current price: $29.01. Market cap: $536.75M.
30-day range: $23.16 to $36.34. Support: $26.04. Resistance: $32.49.
Rigel Pharmaceuticals, Inc. Community Discussion
0Share your Rigel Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.